This is my third BioMarin (NASDAQ: BMRN ) article following 07/2024's "BioMarin Pharmaceutical: Steady Performer Scheduling Its Big Reveal" (" Big Reveal "). In the interim BioMarin has dropped >26%. Whenever a company loses that much that fast a fundamental question arises; is itWriting under the pseudonym "out of ignorance", I very much regard investing as a learning process. Investing failures are tuition paid. Investing successes enter the trove of lessons learned. In my Seeking Alpha articles I share m ...

Core Viewpoint - Investors are increasingly seeking growth stocks, particularly in the financial sector, to achieve above-average returns, but identifying such stocks can be challenging due to inherent volatility and risks [1] Group 1: Company Overview - BioMarin Pharmaceutical (BMRN) is currently highlighted as a recommended growth stock due to its favorable Growth Score and top Zacks Rank [2] - The company operates in the rare disease biopharmaceutical sector, which is characterized by strong growth potential [3] Group 2: Earnings Growth - BioMarin has a historical EPS growth rate of 36.8%, with projected EPS growth of 22.4% for the current year, significantly surpassing the industry average of 11.6% [4] - Double-digit earnings growth is a key indicator of strong prospects and potential stock price gains for growth investors [3] Group 3: Cash Flow Growth - The year-over-year cash flow growth for BioMarin stands at 23.3%, outperforming the industry average of -2.6% [5] - Over the past 3-5 years, the company's annualized cash flow growth rate has been 54.6%, compared to the industry average of 3.3% [6] Group 4: Earnings Estimate Revisions - There has been a positive trend in earnings estimate revisions for BioMarin, with the current-year earnings estimates increasing by 0.3% over the past month [7] - A strong correlation exists between earnings estimate revisions and near-term stock price movements, making this trend significant for investors [7] Group 5: Investment Positioning - BioMarin has achieved a Zacks Rank of 1 (Strong Buy) and a Growth Score of B, positioning it well for potential outperformance in the market [9] - The combination of strong earnings growth, cash flow growth, and positive earnings estimate revisions makes BioMarin an attractive option for growth investors [9]

The macroenvironment in 2025 looks grim as signs of a slowdown in the economy set in. The biotech industry experienced a choppy ride in 2024, and the same is likely in store in 2025. Given the continuous need for innovative medical treatments, irrespective of the state of the economy, the biotech industry will continue to grab investors’ interest despite the inherent volatility and uncertain macroeconomic environment.M&A activity is likely to accelerate in 2025 with a change in administration and expected d ...

Legal Action and Patent Infringement - BioMarin Pharmaceutical Inc has initiated a legal action against Ascendis Pharma A/S for infringement of European patent EP 3 175 863 B1 at the Unified Patent Court (UPC) in Munich, Germany [1] - The patent covers long-acting variants of C-Type Natriuretic Peptide (CNP) [1] - The legal action is based on BioMarin's belief that Ascendis' TransCon CNP investigational product and its development program in Germany and elsewhere in Europe infringe BioMarin's patent [2] - The BioMarin patent was confirmed by the European Patent Office's Opposition Division in 2024 [2] Unified Patent Court (UPC) Jurisdiction - The UPC, which formally started in June 2023, has jurisdiction over European patents for 18 European member states that have ratified the Unitary Patents (UPs) [3] - These member states include Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Portugal, Romania, Slovenia, and Sweden [3] Company Background and Commitment - BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient [4] - The company, founded in 1997, has a proven track record of innovation with eight commercial therapies and a strong clinical and preclinical pipeline [4] - BioMarin is committed to protecting the important inventions its scientists make for patients around the world, including the more than 15 years of scientific research that supported VOXZOGO® and BMN 333, its long-acting CNP [4] Trademarks and Contacts - BioMarin® and VOXZOGO® are registered trademarks of BioMarin Pharmaceutical Inc [6] - Contacts for investors and media are Traci McCarty and Andrew Villani, respectively [7]

Stock Performance and Price Targets - BioMarin Pharmaceutical (BMRN) shares have gained 2.1% over the past four weeks, closing at $67.38 [1] - The mean price target estimate of $98.28 indicates a potential upside of 45.9% [1] - The average price target comprises 25 estimates ranging from $65 to $138, with a standard deviation of $17.42 [2] - The lowest estimate suggests a 3.5% decline, while the most optimistic estimate points to a 104.8% upside [2] Analyst Consensus and Earnings Estimates - Strong agreement among analysts about the company's ability to report better earnings strengthens the view of a potential upside [4] - The Zacks Consensus Estimate for the current year has increased 4.3% over the past month, with one positive revision and no negative revisions [10] - BMRN currently holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks [11] Analyst Behavior and Price Target Reliability - Analysts often set overly optimistic price targets to generate interest in companies with which their firms have business relationships [6] - A tight clustering of price targets, indicated by a low standard deviation, suggests a high degree of agreement among analysts [7] - Empirical research shows that price targets rarely indicate where a stock's price is actually heading [5] Investment Considerations - While price targets should not be entirely ignored, making investment decisions solely based on them could lead to disappointing returns [8] - The direction of price movement implied by the consensus price target appears to be a good guide, even if the target itself is not reliable [12]

SAN RAFAEL, Calif., Jan. 6, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will present at the 43rd Annual J.P. Morgan Conference on Monday, January 13, 2024, at 9:00 am PT / 12:00 pm ET, in San Francisco, California. An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available thro ...

Investors in BioMarin Pharmaceutical Inc. (BMRN) need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 17, 2025 $40 Call had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It c ...

Core Insights - Zacks Premium provides tools for investors to enhance their stock market engagement and confidence, including daily updates, research reports, and stock screens [1][2] Zacks Style Scores - The Zacks Style Scores are indicators that assist investors in selecting stocks likely to outperform the market within 30 days, rated from A to F based on value, growth, and momentum characteristics [3] - The Value Score focuses on identifying undervalued stocks using ratios like P/E, PEG, and Price/Sales [4] - The Growth Score evaluates stocks based on projected and historical earnings, sales, and cash flow to identify sustainable growth opportunities [5] - The Momentum Score helps investors capitalize on price trends by analyzing short-term price changes and earnings estimate shifts [6] - The VGM Score combines all three Style Scores, providing a comprehensive indicator for selecting stocks with attractive value, growth potential, and momentum [7] Zacks Rank - The Zacks Rank is a proprietary model that utilizes earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [8][9] - Investors are encouraged to focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B to maximize returns [11] - Stocks with lower ranks, even with high Style Scores, may still face downward price trends due to negative earnings forecasts [12] Company Spotlight: BioMarin Pharmaceutical - BioMarin Pharmaceutical Inc. specializes in developing treatments for severe medical conditions, primarily in children, and is currently rated 3 (Hold) with a VGM Score of A [14] - The company has a Momentum Style Score of B, with shares increasing by 0.5% over the past four weeks, and has seen upward revisions in earnings estimates for fiscal 2024 [15] - With a solid Zacks Rank and strong Style Scores, BioMarin is positioned as a noteworthy option for investors [16]

A month has gone by since the last earnings report for BioMarin Pharmaceutical (BMRN) . Shares have lost about 1.9% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is BioMarin due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Q3 Earnings & Sales Top EstimatesBioMarin r ...

BioMarin Pharmaceutical TodayBMRNBioMarin Pharmaceutical$63.44 +0.88 (+1.41%) 52-Week Range$61.15▼$99.56P/E Ratio37.99Price Target$94.20Add to WatchlistBioMarin Pharmaceutical NASDAQ: BMRN has been a rough investment for a long time. Over the past 10 years, shares have provided a total return of -28%. However, Wall Street analysts have consistently given this stock price targets that are much higher than its trading price. They see more fundamental value in the company than the market will give it credit f ...